Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens
The survey revealed that improving customer experience (CX) and operational efficiencies are top priorities, which healthcare organizations aim to attain by deploying digital health solutions
This expansion will support the global operations network and help meet global demand for mammalian development services that support Lonza’s manufacturing sites
It has planned an investment of over Rs 80 crore in the next five years
Since its inception, the company has either acquired or taken a majority stake in five companies
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery
Subscribe To Our Newsletter & Stay Updated